Baker Bros. Advisors LP Celldex Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $8.39 Billion
- Q1 2025
A detailed history of Baker Bros. Advisors LP transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 247,644 shares of CLDX stock, worth $5.04 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
247,644
Previous 247,644
-0.0%
Holding current value
$5.04 Million
Previous $6.26 Million
28.18%
% of portfolio
0.05%
Previous 0.07%
Shares
1 transactions
Others Institutions Holding CLDX
# of Institutions
188Shares Held
69.3MCall Options Held
220KPut Options Held
310K-
Wellington Management Group LLP Boston, MA8.35MShares$170 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.5MShares$132 Million9.94% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$95.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.9MShares$79.3 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$76.4 Million1.45% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $951M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...